NYSE:NNVC NanoViricides (NNVC) Stock Price, News & Analysis → Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (From Paradigm Press) (Ad) Free NNVC Stock Alerts $1.90 -0.68 (-26.36%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$1.88▼$2.5850-Day Range$1.10▼$3.3052-Week Range$1.00▼$3.59Volume691,104 shsAverage Volume362,893 shsMarket Capitalization$22.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsTrends Get NanoViricides alerts: Email Address Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About NanoViricides Stock (NYSE:NNVC)NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Read More NNVC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NNVC Stock News HeadlinesJune 11, 2024 | proactiveinvestors.comNanoViricides antiviral candidate 'may be first effective oral nanomedicine'June 11, 2024 | americanbankingnews.comNanoViricides (NYSE:NNVC) Receives New Coverage from Analysts at StockNews.comJune 4, 2024 | proactiveinvestors.comNanoViricides says lead asset exhibits desirable blood concentration profile for infrequent dosingMay 29, 2024 | finance.yahoo.comA First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and MoreMay 29, 2024 | proactiveinvestors.comNanoViricides CEO says lead asset NV-387 could be ‘holy grail' of antiviral medicinesMay 23, 2024 | proactiveinvestors.comNanoViricides taps Aagami to seek out licensing and partnership opportunitiesMay 23, 2024 | finance.yahoo.comNanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.May 21, 2024 | proactiveinvestors.comNanoViricides could generate ‘antiviral superdrug' for multiple diseases, analysts believeMay 20, 2024 | finanznachrichten.deNanoViricides, Inc.: Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential CureMay 20, 2024 | proactiveinvestors.comNanoViricides reports strong antiviral activity of NV-387 against RSVMay 19, 2024 | finance.yahoo.comNanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo FinanceMay 14, 2024 | proactiveinvestors.comNanoViricides unveils new data showing lead drug asset's strong activity against RSVMay 14, 2024 | finance.yahoo.comA Novel Broad-Spectrum Antiviral with Activity Against RSVMay 13, 2024 | proactiveinvestors.comNanoViricides CEO discusses NV-387's broad-spectrum antiviral potentialMay 10, 2024 | proactiveinvestors.comNanoViricides to showcase lead drug asset's progress at EF Hutton Annual Global ConferenceMay 10, 2024 | finanznachrichten.deNanoViricides, Inc.: NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York CityMay 8, 2024 | proactiveinvestors.comNanoViricides says lead asset shows antiviral activity against Smallpox and MpoxMay 8, 2024 | finanznachrichten.deNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/MpoxMay 8, 2024 | finance.yahoo.comNanoViricides, Inc. (NNVC)May 6, 2024 | ca.investing.comNanoViricides drug asset shows ‘superior antiviral effects’ against Influenza AMay 6, 2024 | msn.comNanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare moversMay 6, 2024 | proactiveinvestors.comNanoViricides drug asset shows ‘superior antiviral effects' against Influenza AMay 6, 2024 | finanznachrichten.deNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Influenza AApril 30, 2024 | proactiveinvestors.comNanoViricides completes Phase 1 trial of lead asset NV-387February 26, 2024 | benzinga.comNanoviricides Stock (AMEX:NNVC) Earnings Dates and Earning CallsSee More Headlines Receive NNVC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/15/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NNVC CUSIPN/A CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.66% Return on Assets-66.51% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book1.48Miscellaneous Outstanding Shares11,810,000Free Float11,271,000Market Cap$22.44 million OptionableOptionable Beta0.94 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Anil R. Diwan Ph.D. (Age 65)Executive Chairman, President, CEO & Secretary Comp: $400kMs. Meeta R. Vyas B.S. (Age 65)M.B.A., SB, MBA, Chief Financial Officer Comp: $129.6kDr. Randall W. Barton Ph.D. (Age 77)Chief Scientific Officer Key CompetitorsClearside BiomedicalNASDAQ:CLSDConnect BiopharmaNASDAQ:CNTBVerastemNASDAQ:VSTMLifeVantageNASDAQ:LFVNProPhase LabsNASDAQ:PRPHView All Competitors NNVC Stock Analysis - Frequently Asked Questions How have NNVC shares performed in 2024? NanoViricides' stock was trading at $1.02 at the start of the year. Since then, NNVC stock has increased by 86.3% and is now trading at $1.90. View the best growth stocks for 2024 here. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) posted its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.16) EPS for the quarter. When did NanoViricides' stock split? NanoViricides shares reverse split on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NNVC) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NanoViricides, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NanoViricides With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.